Unicycive Therapeutics Announced Results From The Oxylanthanum Carbonate UNI-OLC-201 Pivotal Trial, Established Favorable Tolerability And Safety And New Drug Application Submission Anticipated In Q3 2024
Unicycive Therapeutics Announced Results From The Oxylanthanum Carbonate UNI-OLC-201 Pivotal Trial, Established Favorable Tolerability And Safety And New Drug Application Submission Anticipated In Q3 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.